Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center

Journal of the Egyptian National Cancer Institute

Table 3 Summary of the treatment change among different subgroups of the 100 patients who had Oncotype DX recurrence score assessment

		Treatment given				Exact sig.
		Endocrine		Chemoendocrine
		n	%	N	%
Treatment Recommendation before RS	Whole group
	Endocrine	46	46	8	8	0.001
	Chemoendocrine	29	29	17	17	0.001
	Luminal A
	Endocrine	32	59.3	8	14.7	0.648
	Chemoendocrine	11	29.4	3	5.6	0.648
	Luminal B
	Endocrine	14	30.4	0	0	< 0.001
	Chemoendocrine	18	39.2	14	30.4	< 0.001
	≤ 50 years
	Endocrine	25	49.1	2	3.9	0.002
	Chemoendocrine	15	29.4	9	17.6	0.002
	> 50 years
	Endocrine	21	41.9	6	12.2	0.115
	Chemoendocrine	14	28.6	8	16.3	0.115
	N0
	Endocrine	42	55.2	7	9.2	0.093
	Chemoendocrine	16	21.1	11	14.5	0.093
	N1
	Endocrine	4	16.7	1	4.2	0.002
	Chemoendocrine	13	54.1	6	25	0.002
	Stage I
	Endocrine	24		5		1.0
	Chemoendocrine	4		1		1.0
	Stages II and III
	Endocrine	22		3		< 0.001
	Chemoendocrine	25		16		< 0.001